Profiles

Gheorghe Doros, PhD

Professor, Biostatistics - Boston University School of Public Health

617-358-2494
doros@bu.edu
Crosstown Center - 331
View Full Profile at BUMC

Biography

Gheorghe Doros is Professor of Biostatistics and director of the Biostatistics Consulting Group. He received his PhD in Statistics from Yale University and joined BUSPH’s Department of Biostatistics in 2006 after spending two years at Eli Lilly, as a member of that company's Drug Discovery and Toxicology department. Dr. Doros’s research on methodological approaches and strategies has been concentrated in the area of clinical trials, more specifically on Bayesian approaches to clinical trials and the area of placebo response in clinical trials. The outcome of his work has been a corner stone in developing a host of collaborations with outstanding faculty, clinicians, and researchers at the Boston University Medical Campus and at other institutions. These productive collaborations have resulted in several federally funded grants. Dr. Doros authored and co-authored many peer-reviewed publications of original and innovative research which has had a major impact on the field. On the majority of publications, Dr. Doros is the lead statistician author. He demonstrated continuing record of multidisciplinary research that has had a major impact on the rapidly changing field. His publications on clinical trials; most proposing the design, analysis and new methodologies or of significant contributions to this field.

Dr. Doros is a very active and effective teacher and mentor in the department of Biostatistics. His teaching philosophy is to pursue an active approach to learning and to engage students to think critically. He taught core and elective courses for Master and PhD-level courses. The excellent course evaluations he received attests to his ability in engaging students in active learning. Dr. Doros has been awarded the excellence in teaching three times in three years.

On a national level, Dr. Doros has served as an Associate Editor for the BioMed Central’s journal Trials and as a reviewer for a number of academic journals. He served as a member of the merit review subcommittee for Epidemiology of the Department of Veteran Affairs and a member NHLBI-Ancillary Studies in Clinical Trials between 2012 and 2014. He has served as a statistical expert on a number of Independent Data Monitoring Committee(IDMC) for clinical trials and clinical programs. He served or seves as a senior consultant on multicenter trials and/or programs for the following organizations Pfizer, Takeda, Avanir, Sarepta and Children's Hospital.

Other Positions

  • Member, BU-BMC Cancer Center - Boston University

Education

  • Yale University, PhD Field of Study: Statistics
  • Yale University, MA Field of Study: Statistics
  • University of Bucharest, MS Field of Study: Statistics
  • University of Bucharest, BS Field of Study: Mathematics

Websites

Classes Taught

  • SPHBS849
  • SPHBS853
  • SPHBS854
  • SPHBS980

Publications

  • Published on 9/2/2025

    Avila Rodriguez AM, Hu X, Varga C, Comenzo R, Sarosiek S, Sloan JM, Sanchorawala V, Doros G, Quillen K. Comparable peri-transplant mortality and incidence of febrile neutropenia after high-dose melphalan and autologous stem cell transplantation in patients with plasma cell dyscrasias treated as outpatient versus inpatient. Br J Haematol. 2025 Oct; 207(4):1679-1683. PMID: 40898649.

     Read At: PubMed
  • Published on 8/29/2025

    Alameddine D, Hamouda M, Doros G, Conte MS, Rosenfield K, Strong MB, Menard MT, Farber A, Hamdan A, Malas M, Ochoa Chaar CI. Insulin therapy and outcomes of revascularization procedures for chronic-limb threatening ischemia in the BEST-CLI trial. J Vasc Surg. 2025 Aug 29. PMID: 40886741.

     Read At: PubMed
  • Published on 8/28/2025

    Jones DW, Farber A, Armstrong DG, Azene E, Duncan A, Todoran TM, Doros G, Strong MB, Rosenfield K, Conte MS, Menard MT. Characteristics of multidisciplinary limb preservation teams and their impact on outcomes in the BEST-CLI trial. J Vasc Surg. 2025 Aug 28. PMID: 40885461.

     Read At: PubMed
  • Published on 8/4/2025

    Beckman JA, Drooz AT, Farber A, Hamdan A, Huber T, Hussein M, Jaff MR, Kashyap VS, McGinigle KL, Menard MT, Rosenfield K, Semel ME, Strong MB, Doros G, Creager MA. The Impact of Coronary Artery Disease in Patients With Peripheral Artery Disease Undergoing Lower-Extremity Revascularization for Chronic Limb-Threatening Ischemia. Circulation. 2025 Aug 05; 152(5):346-348. PMID: 40758772.

     Read At: PubMed
  • Published on 7/21/2025

    Vemulapalli S, Doros G, Weissler EH, Jones WS, Li S, Obrien SM, Beckman JA, Hamburg NM, Jaff MR, Strong MB, Rosenfield K, Menard MT, Farber A, Patel MR. Prediction of 1-Year Major Adverse Cardiovascular Events in Chronic Limb Threatening Ischemia. JACC Adv. 2025 Aug; 4(8):101959. PMID: 40695135.

     Read At: PubMed
  • Published on 6/4/2025

    Siracuse JJ, Kaufman JA, Farber A, Menard MT, Rosenfield K, Conte MS, Schanzer A, Powell RJ, Venermo M, Doros G, Faries P, Strong MB, Dake MD. Antiproliferative endovascular drug technology is associated with fewer major reinterventions after femoropopliteal interventions for chronic limb-threatening ischemia. J Vasc Surg. 2025 Oct; 82(4):1375-1382. PMID: 40464723.

     Read At: PubMed
  • Published on 5/23/2025

    Steflea R, Stroescu RF, Gafencu M, Chisavu F, Stoicescu ER, Doros G. ENDOCRINE AND GROWTH ABNORMALITIES IN CHILDREN WITH KIDNEY FAILURE ON MAINTENANCE HEMODIALYSIS - EXPERIENCE OF A SINGLE CENTER FROM WESTERN ROMANIA. Acta Endocrinol (Buchar). 2024; 20(3):393-400. PMID: 40530097.

     Read At: PubMed
  • Published on 4/22/2025

    Kashyap VS, Beckman JA, Doros G, Menard MT, Rosenfield K, Creager MA, Tuttle KR, McGinigle KL, Huber T, Kinlay S, Drooz AT, Strong MB, Weinberg I, Farber A, Jaff MR. Optimal Medical Therapy Is Associated With Improved Limb Outcomes in PAD Patients: A BEST-CLI Substudy. J Am Coll Cardiol. 2025 Apr 22; 85(15):1568-1572. PMID: 40240095.

     Read At: PubMed
  • Published on 4/4/2025

    Farber A, Menard MT, Conte MS, Rosenfield K, Hicks CW, Doros G, Strong MB, Houlind K, Kolh P, Siracuse JJ. Editor's Choice - Bypass After Failed Endovascular Intervention Is Associated with an Increased Risk of Above Ankle Amputation Among Patients with Chronic Limb Threatening Ischaemia in a Randomised Trial Population. Eur J Vasc Endovasc Surg. 2025 Jul; 70(1):107-113. PMID: 40188865.

     Read At: PubMed
  • Published on 4/3/2025

    Shah KB, Aridi H, Dake MD, Doros G, Farber A, Menard MT, Motaganahalli R, Ochoa Chaar C, Rosenfield K, Scali ST, Shah SK, Strong MB, Upchurch GR, Robinson WP. Age-Related Outcomes After Revascularization for Chronic Limb-Threatening Ischemia: An Analysis of BEST-CLI. Circ Cardiovasc Interv. 2025 Jun; 18(6):e014833. PMID: 40177778.

     Read At: PubMed

View 363 more publications:View Full Profile at BUMC

News & In the Media

View all profiles